Farmorubicin
IV Infusion
Janata TradersGeneric:
Epirubicin HydrochlorideWeight:
2 mg/mlbest Price:
? 2,730.00Generic
Epirubicin Hydrochloride
Dosage Administration
Cyclophosphamide: 75 mg/m� PO D 1-14 Epirubicin: 60 mg/m� IV D 1, 8 5-Fluorouracil: 500 mg/m� IV D 1, 8 Repeated every 28 days for 6 cycles
Contraindications
Most commonly reported adverse effects are- Myelosuppression, cardiotoxicity, alopecia, hyperpyrexia, lethargy, amenorrhoea, nausea, vomiting, diarrhea, fever, rash, anorexia, harmless reddish appearance of urine for 1-2days.
Side Effects
Pregnancy Category D. There are no adequate and well-controlled studies in pregnant women. It should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because of the potential for serious adverse reactions from Epirubicin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pregnancy And Lactation
Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours of equilibration at controlled room temperature (15�-25�C). Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Procedures for proper handling and disposal of anticancer drugs should be used when handling and preparing Epirubicin. Epirubicin Injection should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. Before beginning treatment with Epirubicin, patients should be recovered from acute toxicities (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment. Also, initial treatment with Epirubicin should be preceded by a careful baseline assessment of blood counts; serum levels of total bilirubin, AST, and creatinine; and cardiac function as measured by left ventricular ejection function (LVEF). Patients should be monitored carefully during treatment for possible clinical complications due to myelosuppression. Supportive care may be necessary for the treatment of severe neutropenia and severe infectious complications. Monitoring for potential cardiotoxicity is also important, especially with greater cumulative exposure to Epirubicin.
Therapeutic
Cytotoxic Chemotherapy
Storage Conditions
Store in refrigerator or at 2-8�C. Do not freeze. Protect from light and keep out of the reach of children.
Over The Counter Products
